Keya Medical Receives Strategic Investment
Keya Medical announced today that it has received a strategic investment from Kunlun Wanwei Group, IDG Capital, Shanghai Guofang Parent Fund, and Yahui Capital.
Keya Medical announced today that it has received a strategic investment from Kunlun Wanwei Group, IDG Capital, Shanghai Guofang Parent Fund, and Yahui Capital.
On January 15, 2020, the National Medical Products Administration in China issued the registration certificate approving DeepVessel FFR for clinical use.
The Future Medical 100 Annual Conference was held Dec. 20, 2019 in Beijing Jiuhua Villa. Keya Medical was among the companies listed on the Top 100 List, and DEEPVESSEL FFR made the list of the Top 5 FFR Products in China.
Keya Medical’s non-invasive CT-FFR product, DEEPVESSEL FFR, was officially implemented in Shunde Hospital of Southern Medical University.
As a member of NVIDIA’s Inception Program, CuraCloud has had early access to NVIDIA’s AI development tools, including NVIDIA Clara, the NVIDIA EGX Intelligent Edge Computing Platform, and NVIDIA AGX for embedded systems.
Keya Medical’s non-invasive coronary evaluation software, DEEPVESSEL FFR, was successfully installed at China Civil Aviation General Hospital on Dec. 2, 2019.
Recent Comments